Phase II Study of Intravenous Rexin-G in Osteosarcoma

NCT00572130 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteosarcoma

Interventions

GENETIC: Rexin-G Dose 1
GENETIC: Rexin-G Dose 2

Sponsor

Epeius Biotechnologies